• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Nucl Med . Varying Levels of Inflammatory Activity in Brain and Body of Patients with Persistent Fatigue and Difficulty Concentrating After COVID

tetano

Editor, Senior Moderator
J Nucl Med


. 2025 Sep 11:jnumed.124.269297.
doi: 10.2967/jnumed.124.269297. Online ahead of print. Varying Levels of Inflammatory Activity in Brain and Body of Patients with Persistent Fatigue and Difficulty Concentrating After COVID-19: A TSPO PET Study

Denise Visser[SUP] 1 2 3 [/SUP], Sandeep S V Golla[SUP] 4 2 [/SUP], Xavier Palard-Novello[SUP] 4 5 [/SUP], Sander C J Verfaillie[SUP] 6 7 8 [/SUP], Anouk Verveen[SUP] 6 7 [/SUP], Dook W Koch[SUP] 3 6 [/SUP], Roos M Rikken[SUP] 4 2 [/SUP], Elsmarieke van de Giessen[SUP] 4 2 [/SUP], Pythia T Nieuwkerk[SUP] 6 7 [/SUP], Marijke E den Hollander[SUP] 4 2 [/SUP], Janneke Horn[SUP] 2 9 [/SUP], Caroline M van Heugten[SUP] 10 [/SUP], Menno D de Jong[SUP] 11 12 [/SUP], Cees C van den Wijngaard[SUP] 13 [/SUP], Tessa van der Maaden[SUP] 13 [/SUP], Yvonne M G van Os[SUP] 14 [/SUP], Maria Prins[SUP] 11 15 [/SUP], Johanna M A Visser-Meily[SUP] 16 [/SUP], Patrick Schober[SUP] 17 [/SUP], Robert C Schuit[SUP] 4 2 [/SUP], Michael Kassiou[SUP] 18 [/SUP], Albert D Windhorst[SUP] 4 2 [/SUP], Sara Biere-Rafi[SUP] 19 [/SUP], Brent Appelman[SUP] 11 20 [/SUP], Michele van Vugt[SUP] 11 15 [/SUP], Frederik Barkhof[SUP] 4 2 21 [/SUP], Bart N M van Berckel[SUP] 4 2 [/SUP], Ronald Boellaard[SUP] 4 2 [/SUP], Hans Knoop[SUP] 6 7 [/SUP], Nelleke Tolboom[SUP] 3 [/SUP]



Affiliations
Abstract

A significant number of patients report persistent fatigue and difficulty concentrating after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a condition known as post-coronavirus disease 2019 (post-COVID) syndrome. The underlying mechanisms for these complaints remain poorly understood. Dysregulated immune and neurologic systems may play a role in the pathophysiology of post-COVID syndrome. A target providing direct information on immune activation is the 18-kDa translocator protein (TSPO), which is upregulated in activated microglia. The PET tracer N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)5,7dimethylpyrazolo[1,5a]pyrimidin-3-yl)acetamide ([[SUP]18[/SUP]F]DPA-714) binds with high affinity to TSPO and serves as a biomarker for neuroinflammation. We aimed to assess whole-body inflammatory activity with TSPO PET in individuals with and without persistent severe fatigue and difficulty concentrating 2 y after infection with SARS-CoV-2 as well as its association with complaint severity. Methods: In this cross-sectional cohort study, we evaluated 47 post-COVID individuals, 33 of whom had severe fatigue and difficulty concentrating (age, 50 ± 8 y; 27 ± 9 mo after initial infection) and 14 who did not have these complaints (age, 47 ± 9 y; 25 ± 10 mo after initial infection). All individuals were high-affinity binders according to their TSPO genotype and completed whole-body 60-min dynamic [[SUP]18[/SUP]F]DPA-714 PET with arterial sampling, MRI, genotyping, and questionnaires. Tracer binding was quantified using binding potential for cerebral regions and inhibitory constant or total distribution volume for extracerebral regions. Parameters were compared between 33 individuals with persistent complaints (severe fatigue and difficulty concentrating) and 14 without, and associations between parameters were assessed. Results: We found globally increased cerebral [[SUP]18[/SUP]F]DPA-714 binding in some individuals reporting persistent complaints when compared with individuals without these complaints. No group-level differences were found in extracerebral binding. Large variability in cerebral and extracerebral binding was observed among individuals. Cerebral and extracerebral binding levels were not correlated with each other or with complaint severity. Conclusion: Increased specific [[SUP]18[/SUP]F]DPA-714 binding was found in some individuals with post-COVID syndrome, indicating the presence of an inflammatory subtype and further supporting the role of neuroinflammation in subtypes of post-COVID syndrome.

Keywords: PET; TSPO; [18F]DPA-714; fatigue; imaging; post-COVID.

 
Back
Top